November 04, 2024 at 8:51 am

Stocks making the biggest moves premarket: Trump Media, Talen, Nvidia, Apple and more

Here are some companies making waves in the market before trading hours. Talen Energy, an independent power organization, saw its shares plunge by over 8% following the Federal Energy Regulatory Commission’s rejection to enhance the power dispatched by its Susquehanna nuclear plant, now owned by Amazon. In relation, Constellation Energy and Vistra also saw their… [Read More]
November 01, 2024 at 12:23 pm

Pro-Dex Delivers Strong Q1 Results, Swings to Profit with 25% Revenue Growth and Higher Margins

Pro-Dex, Inc. (NASDAQ: PDEX) announced strong financial results for its fiscal 2025 first quarter. The company reported a 25% increase in net sales, reaching $14.9 million, driven primarily by increased repairs of a surgical handpiece for its largest customer and the initial shipment of a next-generation handpiece. Gross profit rose by 41%, with margins improving… [Read More]
November 01, 2024 at 12:06 pm

Massachusetts Moves to Legalize Psychedelics: Question 4 Sparks Heated Debate Over Safety and Potential Benefits

Massachusetts could soon legalize plant-based psychedelic drugs if a recently proposed measure, known as Question 4, is passed. Set to take effect on December 15, the law would make Massachusetts the third state to allow supervised use of psychedelics, joining Oregon and Colorado. The proposed law, summarized by the state attorney, would permit individuals aged… [Read More]
November 01, 2024 at 11:54 am

Mag 7 Results: Prime Performance for Amazon While Apple Not As Fruitful

This week five of the Mag 7 reported their financial results with a strong Alphabet (GOOG) report followed by less thrilling announcements by Microsoft (MSFT) and Meta (META). Most recent reports come from Amazon and Apple. Since their reports, Amazon is trading up 7% as Apple is trading down 1.5%. Mighty Margins Amazon’s (AMZN) Q3… [Read More]
November 01, 2024 at 11:48 am

Ardelyx Q3 Breakdown: Strong Sales Growth Amid Strategic Shifts and Market Challenges

Ardelyx, Inc. (Nasdaq: ARDX) reported Q3 2024 revenue of $98.2 million, up from $56.4 million in Q3 2023, driven by significant growth in sales of IBSRELA and XPHOZAH. Key Highlights: IBSRELA (tenapanor), to treat irritable bowel syndrome with constipation (IBS-C): Generated $40.6 million in Q3 sales, a 15% increase from Q2 and nearly double the $22.3… [Read More]
November 01, 2024 at 11:07 am

PRISM EV: Ideal Power Receives Orders from Global Tier 1 Auto Supplier

Ideal Power Inc. (IPWR) a pioneer in developing and commercializing the highly efficient B-TRAN™ bidirectional semiconductor power switch, announced today that it has received orders from a global Tier 1 automotive supplier listed on the NYSE. This new customer, a prominent supplier of sensors and electrical protection components for automotive electrification and electric vehicles (EVs),… [Read More]
November 01, 2024 at 11:06 am

New York’s Cannabis Market Primed for Growth: Business of Cannabis Event to Connect Entrepreneurs with Top Investors

New York’s cannabis market continues to attract investor attention, with recent projections suggesting it could grow to $6 billion within the next two years. On November 12, the Business of Cannabis: New York event at the New York Academy of Medicine will offer a platform for cannabis entrepreneurs to connect directly with investors, including Tuatara… [Read More]
November 01, 2024 at 9:54 am

ESSA Pharma Ends Phase 2 Trial for Prostate Cancer Drug Following Lack of Efficacy; Stock Drops 70%

ESSA Pharma (NASDAQ: EPIX) announced the termination of its Phase 2 trial evaluating masofaniten in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer (mCRPC) who had not previously received second-generation antiandrogens. Following an interim analysis that showed no added benefit of masofaniten with enzalutamide over enzalutamide alone, ESSA’s stock dropped 70% premarket. The… [Read More]
November 01, 2024 at 9:45 am

Verastem Oncology Finalizes NDA Submission for KRAS Mutant Ovarian Cancer Therapy, Eyes FDA Decision by Mid-2025

Verastem Oncology (NASDAQ:VSTM) has completed its New Drug Application (NDA) submission to the FDA for the combination treatment of avutometinib and defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC) with a KRAS mutation. LGSOC is a rare and persistent form of ovarian cancer, distinct from high-grade serous ovarian cancer (HGSOC). It is highly… [Read More]
November 01, 2024 at 8:50 am

Stocks making the biggest moves premarket: Amazon, Apple, Atlassian and more

Here’s a look at the companies that caught everyone’s attention before market opening. Amazon — The e-commerce titan’s shares soared 7% following its impressive earnings that surpassed expectations along with solid growth in cloud and advertising. Amazon Web Services revenue experienced a 19% YoY increment. Apple — Despite exceeding top and bottom line forecasts for… [Read More]
October 31, 2024 at 3:23 pm

Mag 7 Moves: Meta and Microsoft Meaningful Metrics Miss

Following Alphabet’s (GOOG) standout report, Meta and Microsoft have provided results that have pushed a sell off of shares for both companies who are now down ~5% on the day. Azure Disappoints on Growth Guidance Microsoft (MSFT) reported strong fiscal Q1 results, exceeding expectations. Azure achieved 34% year-over-year growth, slightly ahead of guidance, with AI… [Read More]
October 31, 2024 at 3:03 pm

Stocks making the biggest moves midday: Peloton, Super Micro Computer, Robinhood, Estee Lauder and more

Discover the companies that are grabbing the spotlight in midday trading. Peloton’s stock catapulted up 28% as the fitness equipment provider announced higher than predicted fiscal first quarter results, enhancing its annual profit forecast. In addition, Ford executive Peter Stern will take over as the new CEO starting January. The pre-owned car marketplace, Carvana, experienced… [Read More]